Navigation Links
Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting

r IV (82 percent) and an ECOG status of 0 or 1 (72 percent); and baseline Hb was 9.5 g/dL in each group.

However, there were more men in the Aranesp group (56 percent) compared to the placebo group (47 percent) and overall survival was worse for men than women (hazard ratio: 1.38 versus 0.99, respectively). More patients received prior chemotherapy in the Aranesp group (73 percent versus 66 percent in placebo). The mean (SD) number of days between prior chemotherapy and first study drug dose was 262 (572) days for the Aranesp group compared to 315 (660) for the placebo arm.

About Aranesp

Aranesp was approved by the U.S. Food and Drug Administration (FDA) in September 2001 for the treatment of anemia associated with chronic renal failure (CRF), also known as chronic kidney disease (CKD), for patients on dialysis and patients not on dialysis. In July 2002, the FDA approved weekly dosing of Aranesp for the treatment of chemotherapy-induced anemia in patients with nonmyeloid malignancies and in March 2006, the FDA approved every-three-week dosing in these patients.

Important Safety Information

Use the lowest dose of Aranesp that will gradually increase the hemoglobin concentration to the lowest level sufficient to avoid the need for red blood cell transfusion (see DOSAGE and ADMINISTRATION in the prescribing information).

Aranesp and other erythropoiesis-stimulating agents (ESAs) increased the risk for death and for serious cardiovascular events when administered to target a hemoglobin of greater than 12 g/dL (see WARNINGS: Increased Mortality, Serious Cardiovascular and Thromboembolic Events).

Cancer Patients: Use of ESAs

-- shortened the time to tumor progression in patients with advanced head and neck cancer receiving radiation therapy when administered to target a hemoglobin of greater than 12 g/dL;

-- shortened overall survival and increased deaths attributed to disease progression at 4 months in patien
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Aranesp ``145 Study Shows No Difference in Survival in Patients with Small-Cell Lung Cancer
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:9/2/2014)... , Sept. 2, 2014 Isis Pharmaceuticals, ... data from three drugs in its lipid franchise were ... of Cardiology (ESC) Congress in Barcelona Spain ... antisense drugs designed to provide effective and safe therapeutic ... is composed of one commercialized drug and several other ...
(Date:9/2/2014)... , Switzerland , September ... receiving ISO 13485 accreditation, Sophia Genetics has become the ... clinical use of a Next Generation Sequencing (NGS) ... certification represents an important step in raising the ... and brings Sophia Genetics, world-leading Data Driven Medicine ...
(Date:9/2/2014)... Sept. 2, 2014  Sinovac Biotech Ltd. (NASDAQ: ... China , today announced that the Company,s management ... , Morgan Stanley Global Healthcare Conference, to be held ... 10, 2014. , Morgan Stanley Asia Pacific Healthcare Day, ... 11, 2014. , Aegis Healthcare & Technology Conference, to ...
Breaking Medicine Technology:Drugs from Isis' Lipid Franchise Highlighted at European Society of Cardiology Congress 2014 2Drugs from Isis' Lipid Franchise Highlighted at European Society of Cardiology Congress 2014 3Drugs from Isis' Lipid Franchise Highlighted at European Society of Cardiology Congress 2014 4Drugs from Isis' Lipid Franchise Highlighted at European Society of Cardiology Congress 2014 5Sophia Genetics Becomes the First European Company to Obtain CE-IVD Mark for Clinical use of Next Generation Sequencing Bioinformatics Pipeline for Routine Genetic Testing 2Sinovac to Participate in Upcoming Investor Conferences 2
... (Nasdaq: ANTH ), a biopharmaceutical company developing ... autoimmune disorders, will release its first quarter 2012 financial ... Anthera will host a conference call at 8:30 am ... Conference Call Access: Date: Friday, May 4, 2012 Time: 8:30 ...
... for Disease Control reports annual deaths involving opioid pain ... in the United States. In New York and North ... abusing prescription medications continues to rise, sparking attention amongst ... care for those suffering from pain. For these reasons, ...
Cached Medicine Technology:Millennium Laboratories Sponsors Educational Programs in Support of Safe Prescribing Practices at Regional Pain Society Conferences 2Millennium Laboratories Sponsors Educational Programs in Support of Safe Prescribing Practices at Regional Pain Society Conferences 3Millennium Laboratories Sponsors Educational Programs in Support of Safe Prescribing Practices at Regional Pain Society Conferences 4
(Date:9/2/2014)... Growing public support for marijuana legalization in the U.S. ... "safer" than other substances, such as alcohol. In January, ... that marijuana is more dangerous than alcohol. Despite the ... use as compared to alcohol use are not well ... Psychosocial Outcomes Associated with Drug Use among US High ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 At the ... Prosupps will be an exhibitor at the Las ... Rd, Las Vegas, NV 89109 Booth #374 Sept 19th ... to encourage healthy living through exercise, diet and supplementation. ... vision, and provide the tools for all Prosupps customers ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 Smile Squared, ... their product offering to include a US-made toothbrush. For ... child without one. , “Smile Squared was created by ... clinic in Guatemala,” said Eric Cope, President of Smile ... sometimes severe dental problems. But many of the same ...
(Date:9/2/2014)... Tuesday 2 September 2014: Digoxin may increase the ... by approximately 20%, according to results from the ROCKET ... Manesh Patel, director of interventional cardiology and catheterisation labs ... US. The findings suggest that caution may be needed ... studies are needed to confirm the observations. , Dr ...
(Date:9/2/2014)... fact that mechanical heart valves increase risks during and ... ROPAC registry presented for the first time today in ... W. Roos-Hesselink, co-chair with Professor Roger Hall of the ... pregnant women with a mechanical heart valve died and ... Of Pregnancy And Cardiac disease (ROPAC) is an ongoing ...
Breaking Medicine News(10 mins):Health News:NYU study compares consequences of teen alcohol and marijuana use 2Health News:NYU study compares consequences of teen alcohol and marijuana use 3Health News:Prosupps, One of the Fastest Growing Supplement Companies, Celebrates a Success Milestone with Exhibiting at the 50th Annual 2014 Mr. Olympia’s Fitness & Performance Expo 2Health News:Smile Squared's Colorful Buy One, Give One Toothbrush Now Available in Schnucks Stores 2Health News:ROCKET AF trial suggests that digoxin increases risk of death in AF patients 2Health News:Mechanical heart valves increase pregnancy risk 2Health News:Mechanical heart valves increase pregnancy risk 3
... Group of the Bellvitge Biomedical Research Institute (IDIBELL) have ... MDM2 protein, stimulates the signalling pathway of another protein, ... senescence (loss of proliferative capacity) in brain cancer, a ... door for MDM2 agonists as new treatments for glioblastomas. ...
... European Molecular Biology Organization (EMBO) today announced Simon Boulton ... Laboratories as the winner of the 2011 EMBO Gold ... outstanding contributions of young researchers in the molecular life ... his groundbreaking research on DNA repair mechanisms. The election ...
... Neuropsychopharmacology (ECNP) is pleased to announce Bertil Fredholm ... Award in Basic Science Research in recognition of ... The ECNP Neuropsychopharmacology Award is presented annually and ... disciplines. The award is accompanied by a prize ...
... HealthDay Reporter , TUESDAY, April 19 (HealthDay News) -- The ... Alzheimer,s disease could double the number of Americans defined as ... the Alzheimer,s Association and the U.S. National Institute of Aging, ... have been in use since 1984. First, Alzheimer,s ...
... What race best describes your background? That one question, ... leave entire groups of people underserved and contribute to ... University published in the current issue of the journal ... patients to identify a single race can alter patterns ...
... in patients with high-grade glioma from chemoradiation may result ... oncologists at the Kimmel Cancer Center at Jefferson ... April issue of the British Journal of ... of early side effects, such as fatigue and loss ...
Cached Medicine News:Health News:Molecule Nutlin-3a activates a signal inducing cell death and senescence in primary brain tumors 2Health News:EMBO Gold Medal 2011 awarded to Simon Boulton 2Health News:EMBO Gold Medal 2011 awarded to Simon Boulton 3Health News:Bertil Fredholm wins the 2011 ECNP Neuropsychopharmacology Award in basic science research 2Health News: Alzheimer's Cases Could Double With New Guidelines: Expert 2Health News: Alzheimer's Cases Could Double With New Guidelines: Expert 3Health News:Limitations of question about race can create inaccurate picture of health-care disparities 2Health News:Minimizing side effects from chemoradiation could help brain cancer patients live longer 2
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
... Products are kept in ... are offered as 1-piece ... or extra long lengths. ... insulation, flush ports, rotating ...
... Instruments incorporate a layered design unique in ... monitored to prevent stray electrosurgical burns along ... insulation failure or capacitive coupling; a well-documented ... into all AEM Instruments provides a neutral ...
Medicine Products: